TLR9 and Epstein-Barr virus infection: CpG oligodeoxynucleotide 2006 triggers innate immunity via the TLR9 of B cells to substantially inhibit BZLF-1 mRNA expression in acute EBV infection ex vivo and in Akata Burkitt lymphoma cells with latent EBV infection stimulated by anti-IgG.